Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cunningham

Showing results (401-410 of 621) with videos related to

Pageof 63
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2008
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphomaRobert Marcus, Kevin Imrie, Philippe Solal-Celigny, et al.
British Journal of Haematology|March 22, 2003
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphomaIan Chau, Mark Harries, David Cunningham, et al.
Cancer Immunology, Immunotherapy : CII|December 3, 2013
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancerNicola E Annels, Victoria E Shaw, Rachel F Gabitass, et al.
European Journal of Cancer (Oxford, England : 1990)|May 31, 2022
Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trialsDrolaiz H W Liu, Nina Šefčovičová, Jake Emmerson, et al.
The Journal of Biological Chemistry|February 27, 2009
Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor designSeungil Han, Anil Mistry, Jeanne S Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) ChemotherapyElizabeth Smyth, Shenli Zhang, David Cunningham, et al.
Blood|April 2, 2020
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPIAmy S Ruppert, Jesse G Dixon, Gilles Salles, et al.
Iscience|April 19, 2021
Teleguided self-ultrasound scanning for longitudinal monitoring of muscle mass during spaceflightJessica M Scott, Meghan Downs, David S Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexedDavid C Farrugia, Hugo E R Ford, David Cunningham, et al.
Journal of the National Cancer Institute|February 8, 2007
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort studyAnthony J Swerdlow, Craig D Higgins, Paul Smith, et al.
Pageof 63

Showing results (401-410 of 621) with videos related to

Sort By:
Pageof 63
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2008
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphomaRobert Marcus, Kevin Imrie, Philippe Solal-Celigny, et al.
British Journal of Haematology|March 22, 2003
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphomaIan Chau, Mark Harries, David Cunningham, et al.
Cancer Immunology, Immunotherapy : CII|December 3, 2013
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancerNicola E Annels, Victoria E Shaw, Rachel F Gabitass, et al.
European Journal of Cancer (Oxford, England : 1990)|May 31, 2022
Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trialsDrolaiz H W Liu, Nina Šefčovičová, Jake Emmerson, et al.
The Journal of Biological Chemistry|February 27, 2009
Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor designSeungil Han, Anil Mistry, Jeanne S Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) ChemotherapyElizabeth Smyth, Shenli Zhang, David Cunningham, et al.
Blood|April 2, 2020
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPIAmy S Ruppert, Jesse G Dixon, Gilles Salles, et al.
Iscience|April 19, 2021
Teleguided self-ultrasound scanning for longitudinal monitoring of muscle mass during spaceflightJessica M Scott, Meghan Downs, David S Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexedDavid C Farrugia, Hugo E R Ford, David Cunningham, et al.
Journal of the National Cancer Institute|February 8, 2007
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort studyAnthony J Swerdlow, Craig D Higgins, Paul Smith, et al.
Pageof 63